- $26.98m
- $1.86m
- 18
- 50
- 89
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.42 | ||
| Price to Tang. Book | 1.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.05% | ||
| Return on Equity | -48.05% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.2 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.
Directors
- Roderick Carter CHM
- Janelle D'Alvise PRE
- Brian Ford CFO (72)
- Pierre Lemieux COO
- Brian Groch OTH
- Jean-Marie Canan IND (65)
- Donald Olds IND (61)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 1st, 2002
- Public Since
- March 7th, 2013
- No. of Employees
- 32
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 9,399,404
- Address
- 3009, LAVAL, H7E 2B5
- Web
- https://www.acasti.com/en
- Phone
- +1 4506864555
- Contact
- Mike Moyer
- Auditors
- Ernst & Young LLP
Upcoming Events for ACST
Q1 2025 Acasti Pharma Inc Earnings Release
Acasti Pharma Inc Annual Shareholders Meeting
Similar to ACST
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Acasti Pharma share price?
As of Today at 19:00 UTC, shares in Acasti Pharma are trading at $2.87. This share price information is delayed by 15 minutes.
How has the Acasti Pharma share price performed this year?
Shares in Acasti Pharma last closed at $2.87 and the price had moved by +0.28% over the past 365 days. In terms of relative price strength the Acasti Pharma share price has underperformed the S&P500 Index by -16.55% over the past year.
What are the analyst and broker recommendations for Acasti Pharma?
The overall consensus recommendation for Acasti Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Acasti Pharma dividend yield?
Acasti Pharma does not currently pay a dividend.
Does Acasti Pharma pay a dividend?
Acasti Pharma does not currently pay a dividend.
When does Acasti Pharma next pay dividends?
Acasti Pharma does not currently pay a dividend.
How do I buy Acasti Pharma shares?
To buy shares in Acasti Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acasti Pharma?
As of the previous close price of $2.87, shares in Acasti Pharma had a market capitalisation of $26.98m.
Where are Acasti Pharma shares listed?
Here are the trading details for Acasti Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACST
What kind of share is Acasti Pharma?
Based on an overall assessment of its quality, value and momentum Acasti Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acasti Pharma share price forecast for 2024?
The analyst consensus target price for shares in Acasti Pharma is $6.01. That is 109.27% above the last closing price of $2.87.
Analysts covering Acasti Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.43 for the next financial year.
What is the trend in the Acasti Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acasti Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +0.27%.
As of the last closing price of $2.87, shares in Acasti Pharma were trading +10.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acasti Pharma PE Ratio?
The Acasti Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acasti Pharma?
Acasti Pharma's management team is headed by:
- Roderick Carter - CHM
- Janelle D'Alvise - PRE
- Brian Ford - CFO
- Pierre Lemieux - COO
- Brian Groch - OTH
- Jean-Marie Canan - IND
- Donald Olds - IND